Sie sind hier: Skip Navigation LinksMental Health Dresden - Leipzig

Prof. Osama Sabri, MD, PhD, Professor of Nuclear Medicine

​Research focus

  • Dementia research (metabolism, perfusion, neuroreceptors, neurotransmitters, amyloid, tau)
  • Psychoses research (depression, schizophrenia)
  • Multimodal imaging (simultaneous PET-MRI acquisitions)
  • Development and clinical use of new cerebral PET radioligands (nicotinic choline receptors, sigma-1 receptors)
  • Adipositas research (serotonin transporter imaging, extrastriatal dopamine receptors)

Official position

Director and Chairman, Department of Nuclear Medicine


Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany 

Business address

Liebigstr. 18
04103 Leipzig

Academic education and degrees

​1981 - 1988

MD in Medicine, School of Medicine, Freie Universität Berlin (FU Berlin)


Doctoral Dissertation, FU Berlin

1989 - 1991

Scientific Researcher, Dept. of Anatomy, University of Bonn

1991 - 1997

Residency in Nuclear Medicine, University of Aachen


State Examination for physician in nuclear medicine (medical specialist)


Venia Legendi (German Habilitation) on the role of PET, SPECT and MRI in vascular dementia, University of Aachen​​


University Professor, Dept. of Nuclear Medicine, University of Leipzig


Professional career

​1989 - 1991

Scientific Researcher, Dept. of Anatomy, University of Bonn

1991 - 1996

Assistant Physician, Dept. of Nuclear Medicine, University of Aachen

1996 - 1998

Senior Physician, Dept. of Nuclear Medicine, University of Aachen

1999 - 2001

Vice-Head and Vice-Chairman, Dept. of Nuclear Medicine, University of Aachen

​Since Oct. 2001

Professor, Director and Chairman (C4) of the Dept. of Nuclear Medicine, University of Leipzig, Germany

May 2008

Call to the „W3-Professur for Nuclear Medicine, University of Aachen" (declined)


Honors, awards and positions


Ludo van Bogaert Award at the International Symposium on SPECT in Clinical Neurology of the World Federation of Neurology, the European Federation of Neurological Societies, and the European Association of Nuclear Medicine (Antwerp, Belgium).


Mallinckrodt Award for Nuclear Medicine of the German Association of Nuclear Medicine (DGN) at the 37th International Annual Meeting of the DGN in Ulm, Germany


Brahms Award for Thyroid Disease of the DGN at the 37th International Annual Meeting of the DGN in Ulm, Germany

Since 1999

Foundation-Member of the inaugural meeting of the Committee for Neuronuclear Medicine of the DGN

2003 - 2008

Chairman (President) of the Committee for Neuronuclear Medicine of the DGN

​Since 2003

Official Member of the Committee „Radiopharmaka" of the DGN


KFAS-Prize ("Arabian Nobel Prize") of the Kuwait Foundation for the Advancement of Sciences (KFAS) for the best nuclear medicine researcher of Arabic origin on the occasion of the official prize ceremony held on 5th December 2005 under the patronage of the former Amir of Kuwait Sheikh Jaber Al-Ahmad Al-Jaber Al-Sabah to honour all winners of „Arabian Nobel Prizes".

Since 2007

Member of the Expert Commission of Nuclear Medicine in Saxony („Fachkommission Nuklearmedizin der Sächsischen Landesärztekammer")

2007 - 2009

Member of the Board of the DGN


Congress President of the 46th Annual Meeting of the German Association of Nuclear Medicine (DGN), Leipzig

2009 - 2011

Member of the Expert Group on Quality Assurance in Medicine of the German Ministry for the Environment ["Qualitätssicherung in der Medizin" der Strahlenschutzkommission des Bundesministeriums für Umwelt, Naturschutz und Reaktorsicherheit (BMU)]

​Since 2009

Official Member of the Scientific Board of the Brain Imaging Council (BIC) of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)


First Place SNM Brain Imaging Council Award – Neurosciences Track of the 58th Annual Meeting ot the SNM Advancing Molecular Imaging and Therapy, San Antonio, Texas, USA


Vice President of the BIC, SNMMI


​President of the BIC, SNMMI


Kuhl-Lassen Award of the SNMMI at the "61th Annual Meeting of the SNM Advancing Molecular Imaging and Therapy", St. Louis, Missouri, USA


10 most important peer-reviewed papers (10 out of 370, Scopus h-index: 62)

  1. Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L …O. Sabri. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol.  Published online July 7, 2020. doi:10.1001/jamaneurol.2020.2526

  2. Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S et al. Cognitive correlates of a4b2 nicotinic acetylcholine receptors in mild Alzheimer's dementia. BRAIN 2018; 141: 1840-1854.  

  3. Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B …O. Sabri. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? J Nucl Med. 2016; 57(11): 1740-1745

  4. Sabri O, Becker GA, Meyer PM, Hesse S, Wilke S et al. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[18F]Flubatine. NeuroImage 2015; 118: 199-208

  5. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akutsu H et al. Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: Phase 3 study. Alzheimer´s & Dementia 2015; 11: 964-974

  6. Schroeter ML, Vogt B, Frisch S, Becker G, Barthel H …O. Sabri. Executive deficits are related to the inferior frontal junction in early dementia. Brain 2012; 135(Pt1): 201-215

  7. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P …O. Sabri. Cerebral amyloid-ß PET with florbetaben(18F) in patients with Alzheimer´s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurology 2011; 10(5): 424-435.

  8. Sabri O, Owega A, Schreckenberger M, Sturz L, Fimm B et al. A truly simultaneous combination of functional transcranial Doppler sonography (fTCD) and 15O-water PET adds fundamental new information on differences in cognitive activation between schizophrenics and healthy control subjects. J Nucl Med 2003; 44: 671-681.

  9. Sabri O, Ringelstein EB, Hellwig D, Schneider R, Schreckenberger M et al. Neuropsychological impairment correlates to hypoperfusion and hypometabolism but not to severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 1999; 30: 556-566

  10. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 1997; 349: 1735-1739​

Foto: Stefan Straube

Semmelweisstraße 10, Haus 13
04103 Leipzig
0341 - 97 24539